All In Biotech

Drug Trial Radar · NCT03400995

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-AK0529 in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Jan 5, 2018

Primary completion

Feb 27, 2018

Study completion Aug 30, 2018

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase I study is to assess the mass balance recovery after a single oral dose of \[14C\]-AK0529 in healthy male subjects.

Conditions

  • Healthy

Interventions

  • AK0529Drug

    A solution containing 300 mg radiolabelled AK0529.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount excreted (Ae)Time frame: At approximately 6 weeks
  2. Percentage of the administered dose (%Ae)Time frame: At approximately 6 weeks
  3. Cumulative recovery (CumAe)Time frame: At approximately 6 weeks
  4. Percentage of cumulative recovery of the administered dose (Cum%Ae)Time frame: At approximately 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Clinical

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.